Overdiagnosis: Thirty Year Study exposes Risks of Mammography

Is looking hard for things to be wrong a good way to promote health?

According to an extensive U.S. study, mammograms have led to more than one million women being “over-diagnosed” with the disease over the past 30 years. This means the mammograms detected tumours that would never have developed into full-blown disease. It also means that many of these women have undergone unnecessary and invasive drug treatment and radical surgery due to misdiagnoses.

  • The study also concluded that mammography had little impact on reducing the number of cases of late-stage breast cancer, and had little effect on the rate of death from breast cancer. This contradicts the cancer industry’s claim that “survival rates” for breast cancer are increasing due to early their interventions and detections.

More Information

Un éditeur torpille l’écrivain Rachel Campergue à l’insu de son plein gré

Max Milo Editions: “provoquer à juste titre”

Déjà dans notre post How to use Self-Publishing to promote a Charity/Cause nous avions vu l’écrivain Judith Barrow dans l’obligation de devenir son propre éditeur afin de pouvoir publier son roman – basé sur des faits réels – Silent Trauma.

Max Milo éditions "Provoquer à juste titre"
Provoquer à juste titre

A-t-on trompé Rachel Campergue, auteure engagée, à l’insu de son plein gré? En lisant Les coulisses de No Mammo ou comment (presque) dégouter un auteur, je me suis dit: “purée, elle a bien morflé...” Le post Résolution de l’énigme nous en apprends plus encore.

Alors peut-être que tout ceci aidera No Mammo? – LE livre référence du droit à l’info objective sur le cancer du sein et les mammogrammes – à entrer encore plus dans la légende…
Sauf que nous préférons les histoires qui finissent bien…

Retrouvez et encouragez Rachel ainsi et son éditeur sur Twitter.

Le Livre “Distilbène, Mon fils n’aura Jamais son bac” maintenant disponible

Préface du docteur Irène Frachon

Distilbène, Mon Fils n’aura Jamais son Bac, de Sylvie Le Cossec
Le livre de Sylvie Le Cossec est disponible pour le Grand Public depuis aujourd’hui

Le livre Distilbène, Mon Fils n’aura Jamais son Bac, de Sylvie Le Cossec – voir le Communiqué de Presse – est disponible pour le Grand Public depuis aujourd’hui 10.01.14 pour 9€. Vous pouvez le commander à: secretariat@grandlargeimprimerie.com.
Retrouvez le livre sur Facebook et Twitter.

Le Distilbène DES, en savoir plus

Oeuvrons ensemble pour la santé du Sein: l’association Seins et Vie

Première cause de décès par cancer pour la femme en France, le cancer du sein est un enjeux majeur de santé publique – 50 000 nouveaux cas par an en France – Chiffres en augmentation dans les pays en développement – 1 femme sur 10 concernée

DES Daughter Network on SlideShare

  • SEVE est un lieu de partage
  • SEVE est un lieu de réflexion
  • SEVE est un lieu d’action
  • Retrouvez SEVE sur le Net, Facebook et Twitter

Follow-up Study of Male and Female Offspring of DES-exposed Mothers

Effects of Diethylstilbestrol on the genital tract of male and female offspring

Abstract #1:

Follow-up study of male and female offspring of DES-exposed mothers
Follow-up study of male and female offspring of DES-exposed mothers

1975 – This is a follow-up study of male and female offspring of mothers who were part of a double-blind placebo controlled investigation during the years 1951-1952, originally aimed at determining the usefulness of Diethylstilbestrol (DES) administration in maintaining pregnancy.

  • So far, 84 DES-exposed females, 43 female controls, 42 DES-exposed males and 37 male controls have been examined.
  • Circumferential ridges of the vagina and cervix were seen in 39% of the DES-exposed females but in none of the controls.
  • Colposcopy revealed vaginal epitheleal changes in 78% of the DES-exposed females 2% of the female controls.
  • Cytology proved to be reliable as a screening test for vaginal epithelial changes in the DES-exposed female.
  • Urine cytology was negative for tumor cells in all patients.
  • The main abnormal finding in the DES-exposed males was that cysts in the epididymis were detected in 10%.
  • No cases of cancer were observed in either the male or female offspring.

Abstract #2:

1977 – This follow-up study presents the effects of DES on the genital tract of male and female offspring of mothers who were part of a double-blind, placebo-controlled investigation during 1951 and 1952 aimed at determining the effect of DES on pregnancy.

  • Epididymal cysts, hypotrophic testes, and capsular induration were the more common genital lesions found in 25% of 163 DES-exposed males as compared to 6% in 168 control males.
  • Semen analysis data on 39 subjects of the DES-exposed group and 25 subjects of the control group showed that 26% of the DES-exposed group produced an ejaculate volume under 1.5 ml; no such cases were observed in the control group.
  • The average values for sperm density ant total motile spermatozoa per ejaculate, although in the normal range, were more than two times lower in the DES-exposed group as compared to the controls.
  • A quality score of greater than 10 (“severely pathologic semen“) was found in 28% of the DES-exposed group as compared to 0 in the control group.
  • An association of pathologic semen quality with physical abnormalities was found only in the DES-exposed group.
  • Two cases of azoospermia, one without genital abnormalities on physical examination and one with bilateral hypotrophic testes were observed so far in the DES-exposed group.
  • Eighteen percent of 229 DES-exposed female patients had irregular menstrual cycles (oligomenorrhea) as compared to 10% of 136 controls.
  • The history of pregnancy revealed a lower incidence of pregnancy in the DES-exposed group (18%) than in the control group (33%).
  • Circumferential ridges of the vagina and cervix were seen in 40% of 229 DES-exposed females but in none of 136 controls.
  • Colposcopic findings in the vagina revealed adenosis in 66.8% of the DES-exposed females and in 3.6% of the control group.
  • Dysplastic lesions were more prevalent in the vagina and cervix of the DES-exposed subjects.
  • No cases of cancer were observed in either the male or female offspring.

NCBI Sources:

  • Follow-up study of male and female offspring of DES-treated mothers a preliminary report
    J Reprod Med. 1975 Jul;15(1):29-32. PMID: 1171234.
  • Follow-up study of male and female offspring of DES-exposed mothers, Obstet Gynecol. 1977 Jan;49(1):1-8. PMID: 318736.
More DES DiEthylStilbestrol Resources

A Side Effect to a Medicine? You can report it using YellowCard

Report Online suspected Side Effects to Medicine Drugs with the MHRA UK Yellow Card Scheme

A Side Effect to a Medicine? Report it using YellowCard, by @MHRApress on Flickr
You can report suspected side effects to a medicine, vaccine, herbal or complementary remedy – online

On Flickr®

Residual Risk of Breast Cancer Recurrence Five Years after Adjuvant Systemic Therapy

Breast cancer patients who undergo AST are at risk of late recurrences

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
JNCI, Oxford University Press USA journal, source for cancer news and information.

About 1 in 5 breast cancer survivors who have completed 5 years of adjuvant systemic therapy (AST) suffer a recurrence within the 10 years after their treatment, according to a 2008 study published in the Journal of the National Cancer Institute.

Context and Caveats

Prior knowledge:

Adjuvant and neoadjuvant systemic therapy (AST) improves the survival of breast cancer patients, but there is still a risk that the disease will recur years later.

Study design:

Disease recurrence among breast cancer patients who were disease free 5 years after AST (the landmark) was estimated 5 and 10 years after landmark. Multivariable analysis was used to identify factors associated with recurrence.

Contributions:

Rates of recurrence-free survival at 5 years and 10 years after landmark were 89% and 80%, respectively. The risk of recurrence 5 years after therapy increased with tumor stage (stage 1: 7%, stage II: 11%, and stage 3: 13%) and was also associated with tumor grade, hormone receptor status, and endocrine therapy.

Implications:

Breast cancer patients who undergo AST are at risk of late recurrences, and this risk is associated with certain characteristics of the original tumor.

Limitations:

HER2/neu status was not included in the analysis because the data were not available; aromatase inhibitor treatment was not included because too few women received it.

Sources and full study:

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy, JNCI, June 2008, Vol 100, Issue 16Pp. 1179-1183.

For DES Daughters

Le grand KOL porteur d’élixir

Médecins, conflits d’intérêts et régulateurs, en images…

KOLporteur d’élixir par @khadok
Le grand KOL porteur omet souvent de présenter les dangers de l’élixir ; parfois, il peut se trouver en situation de conflits d’intérêts

Il était une fois dans une contrée lointaine, un producteur d’élixir. Cet élixir est présenté aux soignants lors de grands rassemblements que nous nommerons plus communément congrès. Présentent-ils un réel intérêt et transmettent-ils une information de qualité au sujet de l’élixir ? Rien n’est moins sûr…

Continuez à lire l’histoire du KOLporteur d’élixir traitant des médecins, médicaments, conflits d’intérêts et régulateurs. Cet article – brillamment mis en images – de Harriague Jean Baptiste nous invite à s’interroger sur le bienfondé du traitement que l’on prend et que l’on prescrit…

Ovarian Cancer Information Leaflet

If you have any concerns about ovarian cancer please speak to your G.P.

It’s a tough one. We talk about sexual health these days in such open terms, but I feel that people just aren’t yet ready to talk about gynaecological cancers.

Ovarian Cancer Information Leaflet, by @TheEveAppealon Flickr
If you have any concerns about ovarian cancer please speak to your G.P.

Download The Eve Appeal Ovarian Cancer Information Leaflet
By The Eve Appeal gynaecology cancer research fund, London UK – on Facebook and Twitter

Watch the Diaporama, and the DES infographics photo set on flickr®  DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact
Email your photos to des.daughter@gmail.com with a short description and title :-)

Our Posts about CancerOvarian Cancer – Women’s Health

Every Breast Implant Operation in England to be recorded on a new Register

BAAPS welcomed a clampdown on unethical advertising, as well as news from the Department of Health that an official breast implant register is to be piloted

Implant register welcomed but must be compulsory

The British Association of Aesthetic Plastic Surgeons welcomed a clampdown on unethical advertising, as well as news from the Department of Health that an official breast implant register is to be piloted. After the dissolution of the original database over seven years ago, the BAAPS has campaigned to have a compulsory system reinstated – particularly since the PIP implant crisis, which saw over 40,000 women in the UK fitted with defective medical devices.

Rajiv Grover, BAAPS President, consultant plastic surgeon, says:

Every Breast Implant Operation in England to be recorded on a new Register
Textured and silicone gel breast implants

At the BAAPS we have been very vocal in our concerns over the tone of aggressive marketing that has been allowed to proliferate unchecked over the last decade, particularly unethical deals and prizes that trivialise life-changing treatment. Whilst we’re pleased there is to be a clampdown on time-linked incentives that place undue pressure on the public, we continue to call for an outright ban on all advertising of medical procedures. People considering cosmetic surgery have a lot to think about: possible risks, their own expectations, the qualifications of the provider, recovery – whether there’s a Christmas sale, a two-for-one if they book by Friday or get Nectar points should never play a part in a sensible decision-making process.”

We are thoroughly relieved that the Government has seen the light in terms of the importance of reinstating the implant register – but the system must be made compulsory, otherwise it is a waste of time. Whilst independent consultants and many reputable groups were able to easily contact their patients during the PIP implant crisis, the scandal shone a light on shoddy recordkeeping from many corners of the sector; with women being given the wrong or no information at all in regards to what had been placed within their bodies. A centralised and comprehensive database is well overdue and essential for the public’s safety and peace of mind. We also call upon the Government to utilise proceeds from such a register for scientific research purposes, specifically into implant safety projects: it is no less than the hundreds of thousands of women undergoing breast surgery deserve.”

Based at the Royal College of Surgeons, the BAAPS is a not-for-profit organisation, established for the advancement of education and practice of Aesthetic Plastic Surgery for public benefit. The BAAPS has also long campaigned for UK-based or equivalent professional indemnity insurance to be compulsory for all surgeons practising in Britain. Members undergo thorough background screening before they can join. Information about specific procedures and surgeons’ contact details can be found on their web site, or by contacting their advice line at 020 7405 2234. Further materials can be posted to members of the public seeking specialised information. BAAPS is also on Twitter and Facebook. For all media enquiries, please email Tingy Simoes.

Sources: Sign me uplift, BAAPS Press release, 29 Dec 2013.

Related press coverage: